Biomarker is a measurable indicator of the severity of the disease. It can be used in targeted therapies for accurate prediction of clinical outcomes across different population and treatments. The demand for new biomarker identification is increasing in recent years due to need for selective therapies, low cost of clinical trials, and growing prevalence of chronic diseases with aging population.
According to the United Nations and the World Bank, in 2018, population aged 60 years or over reached to 673,618,927 from 566,877,560 in 2013. Also, the number of persons aged 80 years or above is projected to increase three-fold between 2018 and 2050, rising from 143 million to 426 million. Moreover, in 2017, it is estimated that over two third of the world’s geriatric population is living in the developing regions compared to developed regions and between 2017 and 2050; the number of people aged 60 years and over in the developing regions is expected to increase more than two-fold, from 652 million to 1.7 billion. This increase in aging population is expected to increase the prevalence of chronic illness such as cancer.
According to GLOBOCAN, in 2012, about 14.1 million new cancer cases were diagnosed across the globe, which increased by ~28% to reach 18.1 million new cases in 2018. This number is further expected to increase by 109.5% to 29.5 million cases by 2040. In addition, according to GLOBOCAN, the mortality due to cancer has also increased in recent years. In 2012, 8.2 million cancer related deaths were recorded globally, which increased by 17% reaching 9.6 million in 2018. Cancer mortality is expected to increase by 58.5% and 100%, reaching 13.0 million and 16.4 million by 2030 and 2040 respectively. Therefore, with increasing incidence of cancer and related mortality, the demand for targeted medicines such as antibodies and research related to curb these illnesses, which is expected to grow in the coming years, thereby driving the growth of research antibodies and reagents market.
The cancer incidence is continuosly increasing in emerging economies like Latin America. In addition, in 2018, Latin America & Caribbean region has registered 1,412,732 new cancer cases, which is expected to increase by 40.1%, reaching 1,979,072 by 2030. Further, these numbers are expected to reach to 2,246,744 and 2,523,200 by 2035 and 2040. In addition, the number of deaths due to cancer is increasing in the region. As per the estimations, in 2018, the number of cancer deaths was 672,758, which is expected to increase by ~93% to reach 1,301,388 deaths by 2040. This increase in cancer prevalence has significantly increased the demand for targeted medicine from the region; thereby drive the drug discovery & development for the disease.
In addition, the government investment on healthcare facilities in the developing region is expected to boost the demand for antibodies and associated reagents. For instance,
- According to Indian Brand Equity Foundation (IBEF), the Indian healthcare sector is growing with fast pace by strengthening coverage, expenditure, and services by both private and public players and stand out as a provider of over 80% of the antiretroviral drugs used globally with total of 3,598 hospitals and 25,723 dispensaries across the country.
- In 2016, China launched 13th Five-Year Plan, which outlines and targets the development of healthcare sector through 2020. This reform was aimed to improve the quality of healthcare services and to step up the ongoing national healthcare reforms to expand access to comprehensive care in both rural as well as urban areas.
- According to the Proteomics Clinical Applications journal, protein array technology based on antibody was used for biomarker discovery in lupus in 2016.
- According to Swedish Trade and Investment, in Brazil, federal law implemented in 2015 has opened up additional areas where foreign capital is allowed for investments in hospitals and clinics; thereby increasing the funding opportunities for healthcare infrastructures. Thus, rising incidence of cancer, aging population, and demand for advanced healthcare therapeutics in these geographies is expected to create significant opportunities for research antibodies market vendors
- According to the Oral Cancer Foundation, antibody-based assays were performed for the identification of oral cancer biomarker in saliva.
- The Royal College of Surgeons in Ireland discovered blood biomarker in drug free schizophrenia patients using multiplex and proteomics immunoassays. A novel approach involving whole auto-antibody mapping was used for scalable biomarker discovery in systemic autoimmune diseases. This led to emergence of the novel approach of biomarker-based cancer diagnosis & therapy. For instance, immunohistochemistry has been used for HER2-targeted therapy in breast cancer patients.
Thus, growing prevalence for biomarker identification using immunohistochemistry, immunoassays increases the adoption of research antibodies; thereby providing an opportunity for market vendors in the forecast period. The global research antibodies and reagents market is expected to grow at a CAGR of 5.6% to reach $6.32 billion by 2027, according to Meticulous Research.